Press releasePRNewswire
Beam Therapeutics
BEAM · NASDAQ
$24.93+$0.74 (+3.06%)TodayMarket closed ·
Prev close $24.19
Latest news
- Press releaseGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM
- NewsErica Kollmann
Top 10 Powder Keg Stocks Where Short Sellers Are Sitting on a Fuse
- Press releaseGlobe Newswire
Beam Therapeutics to Present Initial Data from Phase 1/2 Trial of BEAM-301 in Glycogen Storage Disease Type Ia (GSDIa) at the ESGCT 33rd Annual Congress
- Press releasePRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM
- NewsErica Kollmann
Squeeze Watch: 10 Stocks With Over 33% Short Interest
- Press releasePRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM
- Press releaseGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM
- NewsChandrima Sanyal
Cathie Wood Loads Up On Biotech: 5 ETFs Holding Her Latest Bets
- Press releaseBusiness Wire
BEAM Investors Have Opportunity to Join Beam Therapeutics Inc. Fraud Investigation with SBS Law
- Press releaseGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM
- NewsErica Kollmann
These 10 Stocks Are Squeeze Candidates Waiting to Happen
- Press releasePRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM
- NewsVandana Singh
Beam Therapeutics Targets Accelerated FDA Approval for Base-Editing Treatment
- Press releaseGlobe Newswire
Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026
- Press releaseGlobe Newswire
Beam Therapeutics Appoints Eric Foster as Chief Commercial Officer
- Press releaseGlobe Newswire
Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD)
- Press releaseGlobe Newswire
Beam Therapeutics to Present Updated Data from Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) in Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026
- NewsVandana Singh
Prime Medicine Secures Favorable Arbitration Ruling in Beam Therapeutics Case
- NewsErica Kollmann
Powder Keg Stocks: 10 Most‑Shorted Names Primed For A Monster Squeeze (CORRECTED)
- Press releaseGlobe Newswire
Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-304 for the Treatment of Phenylketonuria (PKU) by the United States (U.S.) Food and Drug Administration
- Press releasePRNewswire
Anti-Aging Cell Therapy Reaches Major GMP Milestone as Wave of Clinical Advancements Gain Momentum
- Press releaseGlobe Newswire
Beam Therapeutics Presents Recently Reported Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the American Thoracic Society (ATS) 2026 International Conference
- Press releasePRNewswire
Beam Therapeutics Supports AlphaDetect to Accelerate Detection of Alpha-1
- Press releaseGlobe Newswire
Beam Therapeutics to Present Updated Biomarker Data from Phase 1/2 BEACON Trial Further Underscoring Risto-cel's Ability to Restore Red Blood Cell Health and Function in Sickle Cell Disease at EHA2026
- Press releaseGlobe Newswire
Beam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates
- NewsAvi Kapoor
Jim Cramer: This Tech Stock Is A 'Winner', Snap Does Not Have Growth
- News
Earnings Summary: Beam Therapeutics Q4
- Press releaseGlobe Newswire
Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU)
- News
Earnings Scheduled For February 24, 2026
- News
Expert Outlook: Beam Therapeutics Through The Eyes Of 4 Analysts
- NewsEvette Mitkov
Beam Therapeutics Stock Surges: What's Driving The Sudden Jump?
- NewsAvi Kapoor
Planet Labs PBC, Day One Biopharmaceuticals, Rxsight, SunOpta And Other Big Stocks Moving Higher On Monday
- NewsAvi Kapoor
Microchip Technology, Alumis, Terrestrial Energy, Bright Minds Biosciences And Other Big Stocks Moving Higher On Tuesday
- NewsErica Kollmann
Cathie Wood's Biotech Trend: Twist, Beam, CRISPR Latest Stock Picks
- Press releasePRNewswire
Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions
- NewsShivdeep Dhaliwal
Cathie Wood Goes All-In On Peter Thiel's Crypto Play Bullish With Back-To-Back Million-Dollar Buys
- Press releaseGlobe Newswire
Beam Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates
- NewsAvi Kapoor
Jim Cramer Sees More Upside For Shopify, Likes CoreWeave's AI Moves
- NewsVandana Singh
Pfizer's Investigational Drug Flunks Late-Stage For Sickle Cell Disease
- Press releaseGlobe Newswire
Beam Therapeutics Reports Second Quarter 2025 Financial Results and Provides Update on BEAM-302 Development Progress in Alpha-1 Antitrypsin Deficiency (AATD)
- NewsRounak Jain
Cathie Wood's Ark Invest Continues To Offload Palantir, Loads Up On Beam Therapeutics, GitLab
- News
10 Analysts Assess Beam Therapeutics: What You Need To Know
- NewsAvi Kapoor
Wolverine World Wide, Pacira BioSciences And Other Big Stocks Moving Higher On Monday
- News
Beyond The Numbers: 9 Analysts Discuss Beam Therapeutics Stock
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.